Glubran(NBCA-MS)胶栓塞脑动静脉畸形临床研究

目的 探讨Glubran(NBCA-MS)胶栓塞脑动静脉畸形的临床技巧及治疗效果.方法 在DSA监测下对96例脑动静脉畸形患者采用不同浓度的意大利GEM公司生产的Glubran(NBCA-MS)胶进行187次血管内栓塞治疗,并对患者进行跟踪随访,了解临床效果.结果 96例患者中临床随访92例未再出现临床症状,症状好转3例,复发1例.48例行脑血管造影复查,其中44例畸形血管团完全消失,其余栓塞程度达80%～90%以上,进一步行γ-刀放射治疗.本组共32例栓塞后行γ-刀放射治疗,其中26例患者治疗1～2年后行DSA造影检查,21例畸形血管团完全消失.结论 用Glubran(NBCA-MS)胶血管内栓塞治疗脑动静脉畸形是一种安全、有效的治疗手段.

Endovascular embolization treatment of cerebral arteriovenous malformation with Glubran (NBCA-MS)

Objective To explore the clinical skills and curative efficacy of Glubran (NBCA-MS) embolization of cerebral arteriovenous malformations. Methods Ninety-six cases of cerebral arteriovenous malformations were treated by 187 endovascular embolizations with different concentrations of Italy GEM company's Glubran (NBCA-MS). Follow-up was performed to 96 cases of cerebral arteriovenous malformation with NBCA-MS embolization. Results During the follow-up in 96 cases, clinical symptoms completely disappeared in 92, were improved in 3 and reoccurred in 1. The malformation was totally got rid of in 44 of 48 cases DSA examinated, and the 80%-90% embolization was achieved in the rest who need further γ-knife therapy. In all cases, γ-knife therapy was performed in 32 cases after embolization, and among them 26 cases received DSA examination 1-2 years after γ-knife therapy, and 21 cases were proved to have no malformation. Conclusions The method ofendovascular emdolization with NBCA-MS is safe, reliable and effective to treat the cerebral arteriovenous malformation.